Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer: A review

Current Opinion in Oncology

Volumn 23, Issue 6, 2011, Pages 594-600

  Mathew, Jacob ^a   Perez, Edith A ^a  

^a MAYO CLINIC   (United States)

Author keywords

antibody drug conjugate; breast cancer; human epidermal growth factor receptor 2; T DM1; trastuzumab emtansine; trastuzumab DM1

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB; TRASTUZUMAB EMTANSINE;

ALOPECIA; ANEMIA; BREAST CANCER; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEVER; HEADACHE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPOKALEMIA; LIVER DYSFUNCTION; LUNG METASTASIS; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; METASTASIS; NAUSEA; NEUTROPENIA; NONHUMAN; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HUMANS; IMMUNOTOXINS; MAYTANSINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ERBB-2;

EID: 80054109854     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32834b895c     Document Type: Review

References (31)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics. CA Cancer J Clin 2010; 60:277-300.
2. Coughlin SS, Ekwueme DU. Breast cancer as a global health concern. Cancer Epidemiol 2009; 33:315-318.
3. Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1994; 1198:165-184.
4. Dawood S, Broglio K, Buzdar AU, et al. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutionalbased review. J Clin Oncol 2010; 28:92-98.
5. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized antip185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996; 14:737-744.
6. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17:2639-2648. (Pubitemid 29415219)
7. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20:719-726. (Pubitemid 34111379)
8. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-792. (Pubitemid 32222155)
9. Montemurro F, Choa G, Faggiuolo R, et al. A phase II study of three-weekly docetaxel and weekly trastuzumab in HER2-overexpressing advanced breast cancer. Oncology 2004; 66:38-45. (Pubitemid 38410678)
10. Burstein HJ, Kuter I, Campos SM, et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001; 19:2722-2730. (Pubitemid 32441378)
11. Jahanzeb M, Mortimer JE, Yunus F, et al. Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(\+) metastatic breast cancer. Oncologist 2002; 7:410-417. (Pubitemid 35266133)
12. Esteva FJ, Valero V, Booser D, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20:1800-1808. (Pubitemid 34273269)
13. Andersson M, Lidbrink E, Bjerre K, et al. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J Clin Oncol 2011; 29:264-271.
14. Valero V, Forbes J, Pegram MD, et al. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J Clin Oncol 2011; 29:149-156.
15. Perez EA, Romond EH, Suman VJ, et al. Original report: 4-year follow-up of trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer: Joint analysis of data from NCCTG N9831 and NSAB B-31. J Clin Oncol 2011; 29:3366-3373.
16. Perez EA, Suman VJ, Davidson NE, et al. Results of Chemotherapy Alone, with Sequential or Concurrent Addition of 52 Weeks of Trastuzumab in the NCCTG N9831 HER2-Positive Adjuvant Breast Cancer Trial [Abstract #80]. Cancer Res 2010; 70:5640.
17. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353:1673-1684. (Pubitemid 41464706)
18. Baselga J, Norton L, Albanell J, et al. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998; 58:2825-2831. (Pubitemid 28311914)
19. Pegram M, Hsu S, Lewis G, et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999; 18:2241-2251. (Pubitemid 29186925)
20. Konecny GE, Thomssen C, Luck HJ, et al. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. J Natl Cancer Inst 2004; 96:1141-1151. (Pubitemid 39207050)
21. Burstein HJ, Keshaviah A, Baron AD, et al. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer 2007; 110:965-972. (Pubitemid 47312860)
22. Lewis Phillips GD, Li G, Dugger DL, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008; 68:9280-9290.
23. Lu D, Krop I, Modi S, et al. Pharmacokinetics (PK) of trastuzumab-DM1 (T-DM1) and paclitaxel (T) in patients with HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with a trastuzumabcontaining regimen. Abstract P3-14-06. Cancer Res 2010; 70(Suppl 1): 293s-294s.
24. Krop IE, Beeram M, Modi S, et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 2010; 28:2698-2704.
25. Holden SN, Beeram M, Krop IE, et al. A phase I study of weekly dosing of trastuzumab-DM1 (T-DM1) in patients (pts) with advanced HER2\+ breast cancer (BC). J Clin Oncol 2008; 26:1029.
26. Burris HA, Rugo HS, Vukelja SJ, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2011; 29:398-405.
27. Krop IE, Lorusso P, Miller KD, et al. A phase 2 study of the HER2 antibody-drug conjugate trastuzumab-DM1 (t-DM1) in patients with HER2-positive metastatic braest cancer previously treated with trastuzumab, lapatinib, and chemotherapy [abstract]. Annals Oncol 2010; 21(suppl 8): 2770.
28. Perez EA, Dirix L, Kocsis J, et al. Efficacy and safety of trastuzumab-DM1 versus trastuzumab plus docetaxel and HER2-positive metastatic breast cancer patients with no prior chemotherapy for metastatic disease: preliminary results of a randomized, multicentric, open-label phase 2 study (TDM 4450G) [abstract] Ann Oncol 2010; 21(suppl 8):viii2.
29. Baselga J, Gelmon KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010; 28:1138-1144.
30. Gianni L, Pienkowski T, Im Y-H, et al. Neoadjuvant pertuzumab (P) and trastuzumab (H): antitumor and safety analysis of a randomized phase II study ('NeoSphere'). Cancer Res 2010; 70 (24 Suppl).
31. Dieras V, Harbeck N, Albain K, et al. A phase Ib/II trial of trastuzumab-DM1 with pertuzumab for patients with HER2-positive, locally advanced or metastatic breast cancer: interim efficacy and safety results. San Antonio Breast Cancer Symposium Poster [p3-14-01], 2010.